This is a multi-center, open phase II clinical study, in patients with unresectable stage III non-small cell lung cancer,to evaluate the effectiveness and safety of Almonertinib induction therapy, and ,to evaluate the effectiveness and safety of different treatment decisions guided by ctDNA dynamic monitoring after local treatments (surgical or radical radiotherapy) evaluated by MDT.~The study includes a screening period (not more than 28 days after the subject signs informed consent to before the first medication), treatment period (including induction\MDT+topical therapy\adjuvant or consolidation therapy) and follow-up period (including safety and survival) .~Eligible subjects received 110 mg of Almonertinib once a day for 8 consecutive weeks of induction therapy; local treatment (surgical or radical radiotherapy) was selected after MDT assessment. In patients with no disease progression after Almonertinib treatment for 2 years, it is up to the investigator to decide whether to continue taking the drug.~Operable subjects were randomly assigned to groups A and B after surgery: Group A received 110 mg of Almonertinib once a day for 2 years, and Group B received Almonertinib ctDNA dynamic monitoring guided treatment (every 3 months test ctDNA once, if it is positive, continue to receive Almonertinib 110 mg once a day, if it is negative, stop Almonertinib until ctDNA turns positive and receive Almonertinib treatment again).~Inoperable subjects were randomly assigned to groups C and D after radical radiotherapy. Group C continued to receive Almonertinib 110 mg once a day for 2 years, and group D received Almonertinib ctDNA dynamic monitoring guided treatment (every 3 months test ctDNA once, if it is positive, continue to receive Almonertinib 110 mg once a day, if it is negative, stop Almonertinib, if ctDNA turns positive, you can receive Almonertinib again).
This is a multi-center, open phase II clinical study, in patients with unresectable stage III non-small cell lung cancer,to evaluate the effectiveness and safety of Almonertinib induction therapy, and ,to evaluate the effectiveness and safety of different treatment decisions guided by ctDNA dynamic monitoring after local treatments (surgical or radical radiotherapy) evaluated by MDT.~The study includes a screening period (not more than 28 days after the subject signs informed consent to before the first medication), treatment period (including induction\MDT+topical therapy\adjuvant or consolidation therapy) and follow-up period (including safety and survival) .